Dr. Shieh-Newton has significant experience in a wide range of life sciences and clean technology industries that allows her to provide creative solutions and render business-savvy advice to her clients. Her practice focuses on patent strategy, comprehensive portfolio management, construction of valuable portfolios, preparation and prosecution of patent applications, interferences, and post-grant proceedings in the life sciences and clean technology sectors. She manages and conducts due diligences for both private and public companies and investors. Dr. Shieh-Newton has been the primary IP counsel on many deals on behalf of investment bankers and underwriters for IPOs and ATMs and other public offerings totaling hundreds of millions of dollars. Dr. Shieh-Newton has also worked on a number of reverse mergers and also represented companies on their securities disclosures for offerings in the capital markets. She has also worked with venture capitalists on due diligence assessment for investments and landscape analysis for formation of new funds and companies.
In addition, Dr. Shieh-Newton’s practice includes assessing freedom-to-operate positions and rendering patentability and invalidity opinions. She has extensive experience in evaluating patent landscapes to advise clients seeking to enter competitive markets, as well as advising clients on third party challenges and risk mitigation strategies. Dr. Shieh-Newton has worked on several biotechnology patent litigations.
Dr. Shieh-Newton has worked on a wide variety of technical areas including antibodies, biologics and biosimilars, immune-oncology (including chimeric T-antigen receptors), immunotherapy, stem cells, regenerative medicine, gene therapy, synthetic biology, microbiomes, enzymes, protein engineering, protein production and therapeutics, vaccines and adjuvants, diagnostics and biomarkers, cancer, biofuels, microbial engineering, industrial fermentation, production of target chemical using biological processes, and quantum sensors, amongst other subject matters.
Dr. Shieh-Newton has worked with emerging companies, universities, as well as larger companies. Representative matters include work done for DuPont/Danisco/Genencor, Regeneron, Roche, Genentech, Goodyear Rubber & Tire Company, Ariosa, University of California, Stanford University.
More Legal and Business Bylines From Terri Shieh-Newton, PhD
- Navigating AI Integration: USPTO's New Guidance for Patent and Trademark Practices - (Posted On Thursday, May 09, 2024)
- USPTO Issues Guidance on AI Use to Patent Professionals — AI: The Washington Report - (Posted On Tuesday, April 23, 2024)
- Picture Claims as an Effective Patent Strategy: Top 10 Reasons to Precisely Tailor Your Patent Claim - (Posted On Wednesday, September 06, 2023)
- Supreme Court Unanimously Affirms Amgen Repatha® Antibody Patents Invalid for Lack of Enablement - (Posted On Thursday, May 25, 2023)
- Examining Art Units to Avoid Subject Matter Eligibility Challenges for Bioinformatics and AI-related Patents - (Posted On Monday, November 22, 2021)
- AI in Biotech and Synthetic Biology: What Can Be Protected? What Should Be Kept Secret? - (Posted On Wednesday, August 11, 2021)
- Life Sciences Newsletter — October 2020 - (Posted On Tuesday, October 20, 2020)
- Patenting Considerations for Artificial Intelligence in Biotech and Synthetic Biology – Part 2: Key Issues in Patent Subject Matter Eligibility - (Posted On Thursday, January 30, 2020)
- Patenting Considerations for Artificial Intelligence in Biotech and Synthetic Biology - (Posted On Monday, September 30, 2019)
- Extension of U.S. Patent and Trademark Office’s Cancer Immunotherapy Pilot Program - (Posted On Wednesday, June 28, 2017)